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Abstract: Viral hemorrhagic fevers (VHF) are acute
zoonotic diseases that, early on, seem to cause platelet
destruction or dysfunction. Here we present the four
major ways viruses affect platelet development and
function and new evidence of molecular factors that are
preferentially induced by the more pathogenic members
of the families Flaviviridae, Bunyaviridae, Arenaviridae, and
Filoviridae. A systematic search was performed through
the main medical electronic databases using as parame-
ters all current findings concerning platelets in VHF.
Additionally, the review contains information from con-
ference proceedings.
Introduction
Viral hemorrhagic fevers (VHFs) are a group of zoonotic
diseases characterized by fever and bleeding disorders that can
progress to shock and death. They are caused by different groups
of viruses from the families Flaviviridae, Bunyaviridae, Arenaviridae, and
Filoviridae [1,2]. In addition to the VHF syndrome, these viruses
have other common characteristics: they are enveloped viruses
with ssRNA genomes and cytoplasmic replication; some of them
share common viral sequences; and they use rodents, bats, or
insects as natural reservoirs or vectors. Their circulation is
geographically restricted by the habitats of their natural hosts,
and human beings are incidental hosts. Outbreaks of VHF occur
sporadically; consequently, these viruses are continuously emerg-
ing or re-emerging in places where they find the ideal conditions.
Most of these viruses are pantropic, and dendritic cells (DC),
monocytes and/or macrophages are among the targets. Some
subsets of those cells are highly susceptible to VHF, producing a
large amount of virus early after infection that modifies the cell’s
antigen-presenting and cytokine-producing functions [3–8]. This
could contribute to the pathogenesis observed in most of the
VHFs, in which severe cases are associated with uncontrolled viral
replication and high levels of viremia. Unfortunately, more disease
treatment possibilities and immune prevention options are needed
(Table 1) [2].
Impact and Epidemiology of VHF
The exploitation of new ecological niches by human beings and
increased travel and trade have promoted the emergence or re-
emergence of VHF around the world (Figure 1). All VHFs are
considered zoonotic diseases and their transmission mechanism
varies from virus to virus. For instance, infection may be through
insect bites or through contact with meat or excreta from infected
animals.
Prioritizing the impact of each of these VHF diseases is
important in order to develop effective control and prevention
methods and reduce the annual loss of life. Together VHF diseases
affect more than 100 million people around the world and kill
more than 60,000 annually. The epidemiology and transmission of
each disease differs greatly (Table 2).
Dengue virus (DENV) from the Flaviviridae is the most prevalent
arthropod-borne VHF. Dengue is present on all continents, with
new cases occurring and spreading to non-endemic areas in the
United States and Europe (Figure 1; Table 2) [9–12]. Between 50–
100 million cases of dengue fever and around 500,000 cases of
dengue hemorrhagic fever (DHF) or shock syndrome (DSS) are
reported every year, with estimated case fatality rates ranging
between 1% and 5% [13]. Yellow fever (YF) virus, another
flavivirus, is the second most globally distributed arthropod-borne
disease, causing around 200,000 cases per year, with case fatality
varying between 15% and 30%. Although there is an effective
vaccine against YF disease, the number of infected people has
increased in recent years, especially in urban Africa [14,15].
Kyasanur Forest disease virus (KFDV), also a flavivirus, circulates
in mammals and birds from India, Saudi Arabia, and Republic of
China. KFDV is transmitted by forest ticks to humans and
nonhuman primates, causing a severe febrile illness, sometimes
with hemorrhagic symptoms [16]. Alkhumra virus, another
flavivirus and a member of the mammalian tick-borne encephalitis
group, is associated with acute VHF in Saudi Arabia, with fatality
rates between 2% and 10% [17,18].
Lassa fever virus (LASV) and Lujo virus (LUJV), from the Old
World subset of the Arenaviridae, are both from Africa. LASV is
transmitted by rodents and causes around 300,000 cases of Lassa
fever (LF) each year in West Africa, with an overall fatality rate
around 1% that can range between 15% and 30% during hospital
outbreaks [19,20]. LUJV was isolated in South Africa during a
human outbreak characterized by nosocomial transmission and
high fatality rates [21]. Since this outbreak, no new cases have
been reported and its reservoir is still unknown. Junin (JUNV),
Machupo (MACV), and Guanarito (GTOV) belong to the New
World subset of the Arenaviridae and, together, are known as South
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American hemorrhagic fever (HF) viruses. These viruses circulate
in rodents and occasionally are transmitted to human beings
through the urine or feces of their carriers. JUNV causes
Argentinian HF (AHF), with case fatality between 15% and
30%. Since the introduction of the attenuated Candid #1 vaccine
the number of AHF cases has decreased dramatically [22,23].
MACV is responsible for Bolivian HF (BHF), with 13 cases of the
disease reported in 2012 and seven deaths [24]. GTOV causes
Table 1. Common characteristics of hemorrhagic fever viruses.
Enveloped viruses with a ssRNA genome
Filovirus, Bunyavirus, and Arenavirus share some genomic sequences
Cytoplasmic replication
They are pantropic viruses that target primary dendritic and monocyte/macrophage cells
Sporadic outbreaks
Infection in human beings is generally asymptomatic or with flu-like symptoms
Severe cases are associated with high levels of virus in blood
Gastrointestinal and neurological symptoms
Rodents or insects are natural reservoirs or vectors
Continuously emerging or re-emerging
Geographically restricted by the presence of its natural host
Limited treatment options
doi:10.1371/journal.pntd.0002858.t001
Figure 1. Geographical distribution of Viral Hemorrhagic Fevers (VHF). This map shows the global distribution of some members of the
viral families related to hemorrhagic fever disease. CCHF stands for Crimean Congo Hemorrhagic Fever and SFTS for severe fever with
thrombocytopenia syndrome.
doi:10.1371/journal.pntd.0002858.g001
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Venezuelan HF in the western part of the country, with an
estimated case-fatality rate of 23% [25]. Between 2011 and 2012,
more than 85 people acquired this disease [26].
Hantaan virus, Seol virus (SEOV), Crimean-Congo Hemor-
rhagic Fever (CCHF) virus, Rift Valley Fever virus, and Severe
fever with Thrombocytopenia Syndrome (SFTS) virus belong to
the family Bunyaviridae. These viruses gained importance in the last
decade because they have been reported in places in which they
are not endemic, with a tendency to continue expanding their
circulation to other regions. Hantaan virus and SEOV, harbored
and transmitted by contact with infected rodent excreta, cause
close to 200,000 Hemorrhagic Fever with Renal Syndrome
(HFRS) cases each year, with case fatality rates from 1% to 16%
in Asia and the Far East Region of the Russia Federation [27].
Nephropathia epidemica, a mild form of HFRS caused by Puumala
virus, is the most prevalent hantaviral disease in Western and
Central Europe. All these viruses are widely distributed and
continue to expand to new regions [28,29]. CCHF is a sporadic
but often-fatal, tick-borne disease that is expanding through
Europe, Asia, and Africa [30,31]. Rift Valley Fever virus is
transmitted by mosquitos and also causes sporadic outbreaks of
hemorrhagic fever in some African countries and, more recently,
the Arabian peninsula, with variable mortality rates [32,33]. SFTS
virus has recently emerged in China and Japan with mortality
rates between 12% and 30% [34,35]. SFTS life cycle is still
unknown; however, seroconversion and virus isolation involve
domesticated animals as reservoirs and ticks as vectors [36]. It has
been suggested that SFTS can also be transmitted through blood
or personal contact with an infected patient [37].
Ebola and Marburg viruses (from the family Filoviridae) cause
sporadic outbreaks amongst human and nonhuman primates in
Central Africa (and recently, West Africa), with very high case
fatality rates, ranging from 25% to 90% [38,39]. These viruses are
most often transmitted by direct contact with infected animals or
people. The natural reservoirs for filoviruses are thought to be bats
[38,40].
Only two vaccines are licensed to prevent VHF: YF17D and
Candid#1, live-attenuated versions of the YF virus and JUNV.
Unfortunately, the VHF-endemic areas are expanding, with the
aggravation that treatments are limited or nonexistent. For this
reason, it is important to continue research and development for
new prevention and control options.
Clinical Signs and Laboratory Findings
VHF signs and symptoms range from asymptomatic infec-
tion to life-threatening disease. Initially, patients develop a
nonspecific febrile syndrome (flu-like) that can include chills,
malaise, headache, backache, arthralgia, myalgia, retro-orbital
pain, anorexia, nausea, vomiting, diarrhea, cough, and sore
throat [41–46]. At this stage the clinical signs resemble other
infectious diseases, making early VHF clinical diagnoses
impossible. Some cases progress to severe disease characterized
by systemic vascular damage that, depending on the virus, will
manifest as subcutaneous bleeding (flushing, conjunctivitis,
peri-orbital edema, petechiae, or ecchymosis), positive tourni-
quet test, hypotension and internal organ bleeding, hematem-
esis, and melena [41–46]. The cause of bleeding in most VHF
diseases is a disseminated intravascular coagulation (DIC) that
depletes the coagulation factors, inducing massive plasma
leakage, hypovolemia, and shock. A prolonged shock state
leads to multiple organ failures and, in some cases, death.
However, the loss of blood is rarely the cause of death (with the
exception of filoviruses) [41–46].
Table 2. Impact of hemorrhagic fever viruses.
Virus Disease name Cases/year Estimated % fatality rate Death/year
Dengue Dengue Fever 50–100 million [131]
Dengue HF (DHF) 500,000 DHF [13] 1%–5% 22,000 DHF/DSS
Dengue shock syndrome (DSS)
Yellow Fever Yellow Fever 200,000 [15] 15%–30% 30,000
Kyasanur forest disease
virus
Kyasanur forest disease 100–500 [132] 2%–10% 1
Alkhumra virus HF 11 [17,18] 2%–10% 3
CCHF Crimean-Congo HF 68 [31,133] 30%–60% 3
Hantaan virus Hemorrhagic fever with renal syndrome
(HFRS)
200,000 [27] 1%–15% 10,000
Rift valley fever 34 [134] 1% 17
SFTS Severe fever with thrombocytopenia
syndrome (SFTS)
171 [34] 12%–30% 21
Lassa Lassa fever 300,000 [19] 1%–15% 5,000
Lujo HF 5 80% 4
Junin Argentinian HF 300–800 [23] 15%–30% 300 (before vaccine)
Machupo Bolivian HF 13 [24] 18%–20% 7
Guanarito Venezuelan HF 85 [26] 23.1%
Ebola Ebola HF 56 [135] 50%–90% 37
Marburg Marburg HF 18 [39] 25% 9
Total Hemorrhagic fever = HF ,51–101 million ,67,000
doi:10.1371/journal.pntd.0002858.t002
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The hallmark characteristic of all VHF is a decrease in platelet
numbers and/or function. This decrease is usually accompanied
by an increase in fibrinogen degradation products, prothrombin
time (PT), and partial thromboplastin time (PTT). At least five
days after the onset of fever, there is also a marked leucopenia and
high viral loads that are associated with fatal outcomes. Another
common finding is an increase in the alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) enzymes, primarily
due to liver damage [41–46].
VHF Pathogenesis
Based on some clinical and laboratory findings (Table 3),
different pathogenic mechanisms have been proposed for each
VHF, including depletion of hepatic coagulation factors, cytokine
storm, increased permeability by vascular endothelial growth
factor, complement activation, and DIC. In spite of the differences
seen with each VHF, there is a large body of evidence indicating
that viral replication and host immune responses play an
important role in determining disease severity and clinical
outcome [47–50]. HF viruses can establish nonlytic replication, or
‘‘virus factories,’’ in monocytes and/or macrophage and DC
[47,49]. Viral replication subverts the function of these cells, as
well as the function of uninfected bystander cells, to undermine the
innate immune response, such as interferon (IFN) production. This
leads to uncontrolled viral replication and to a lack of specific
antiviral responses in the host [47–50]. These cells might also act as
vehicles to carry the virus to its replication sites, such as
endothelium, liver, spleen, and other organs, leading to the
pantropism of most hemorrhagic fever viruses [47–50]. Whereas
the early replication stage is characterized by a lack of IFN
production and IFN-responsive gene expression, later viremic stages
reveal an unregulated release of pro-inflammatory cytokines, such
as tumor necrosis factor alpha (TNF-a), IL-10, IL-1Ra, and soluble
TNF-R, that could contribute to immunosuppression and increased
vascular permeability, leading to hemorrhagic signs [51,52].
Thrombocytopenia (reduction of platelet numbers) and de-
pressed immune responses are hallmarks of VHF, and platelets are
involved in both processes; therefore, this review will focus on the
platelet’s role in VHF pathogenesis.
Platelet Structure and Functions
Platelets, also known as thrombocytes, are small, 2–3 mm,
enucleated cell fragments derived from the cytoplasm of large,
100 mm, megakaryocytes (MKs) located in the bone marrow
(Figure 2) [53]. Each MK sheds thousands of platelets into the
blood stream, making them the second-most-abundant cell type in
peripheral blood. Platelets’ most-known function is to maintain the
integrity of the vascular system [53]; however, their function as
immune elements is becoming more evident.
Under specific stimulus, such as tissue damage, platelets are
activated by extracellular matrix proteins, such as collagen and
von Willebrand factor. Their irregular shapes swell to a compact
spherical form with projections containing glycoprotein receptors
that help them to attach to each other and to cells at wound sites
[54]. After activation, platelets release granule contents and
coagulation factors that further enhance their activation and cell
attachment (Figure 3). This process results in the formation of an
effective plug at the site of injury that supports formation of a
fibrin network and stops bleeding [55].
There are some pathological processes in which the normal
number of circulating platelets can decrease (thrombocytopenia),
increase (thrombocytosis), or diminish in function (thrombasthe-
nia) with or without hemostatic manifestations. The study of those
conditions showed that in addition to their role in homeostasis,
platelets are important mediators of inflammation and innate
immunity [56]. Sub-products generated from microorganisms,
from complement fixation reactions, or from expression of
receptors such as Fc and C3a/C5a can attract platelets to the
site of infection or injury where they are activated by thrombin
and bind to vascular endothelial cells and leukocytes. Platelets can
also bind pathogens directly, recognizing them through Toll-like
receptors (TLRs), and can alert other cells via the innate immune
response [57]. Platelets can directly release antimicrobial factors
such as platelet factor 4 (PF-4), RANTES, connective tissue
activating peptide 3 (CTAP-3), platelet basic protein, thymosin b-4
(Tb-4), fibrinopeptide B (FP-B), fibrinopeptide A (FP-A), superox-
ide, hydrogen peroxide, and hydroxyl free radicals. Additionally,
platelets participate in antibody-dependent cell cytotoxicity against
microbial pathogens [58].
In conclusion, any pathogenic state affecting platelets will not
only impact hemostasis but also will modify the immune response
to infection. Although there are some advances in understanding
the specific platelet activation mechanisms induced by some
microorganisms, little is known about these interactions and their
role in the pathogenesis of VHF.
Direct and Indirect Virus–Platelet Interactions
Several microorganisms or molecules derived from them
interact with platelets and affect their function [55,59,60].
Virus–platelet interactions were initially described around 50
years ago with some in vitro experiments using influenza virus and
other myxoviruses [61,62]. Since then, other viruses have been
reported to interact not only with platelets but also with MKs [63–
68]. From these interactions, platelet numbers or functions can be
compromised, and little is known about the exact mechanisms. In
the case of VHF, recent publications described pathogenic
mechanisms involving the role of platelets in homeostasis as well
as their role in the initial immune responses in animals and human
beings. The next paragraphs will describe different ways in which
hemorrhagic fever viruses affect platelets.
There are four major causes of thrombocytopenia or platelet
malfunction induced by viruses. These include direct effects of
viruses on platelets, immunological platelet destruction, impaired
megakaryopoiesis, and MK destruction (Table 4) [68]. In the VHF
diseases, the most common mechanism of thrombocytopenia is
platelet disappearance from damaged tissues or generalized virus-
induced DIC, in which coagulation factors are depleted. This
common pattern does not seem to apply to LASV. Additionally,
there is some evidence that viruses not belonging to the
hemorrhagic fever group (such as varicella, herpes zoster,
smallpox, rubella, measles, cytomegalovirus, rotavirus, adenovirus,
and HIV), under specific circumstances, can also cause hemostatic
problems and can be associated with DIC [66,69–72]. More work
is necessary to clarify the role of the platelet–virus interaction in
coagulopathies and in DIC induced by both hemorrhagic and
nonhemorrhagic viruses.
Platelet–Virus Binding
Platelets bind viruses through different receptors, such as b-3
integrins or TLRs, and platelets are known to express TLR2,
TLR4, and TLR9 [73,74]. In severe sepsis, there are coagulation
abnormalities and DIC that are thought to be due to TLR
signaling in platelets [57]. Bacterial stimulation of platelet TLR2
increased P-selectin surface expression, activation of integrin
aIIbb3, generation of reactive oxygen species, and formation of
platelet–neutrophil heterotypic aggregates in human whole blood
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[75]. Members of the family Bunyaviridae have been shown to bind
platelets; specifically, hantaviruses bind to avb3 or aIIbb3 integrins
expressed on platelets and endothelial cells, contributing to viral
dissemination, platelet activation, and induction of endothelial cell
functions. These events reduce the number of circulating platelets
and increase vascular permeability [74,76].
Platelets can also be activated by exposure to virus-infected cells.
When HUVEC cells are infected with DENV, and then exposed
to human platelets, the platelets become activated and bind to the
endothelial cells [77]. Several viruses have shown in vitro affinity
for the integrin receptors on both platelets and vascular
endothelial cells: e.g., aVb3 binds coxsackievirus A9, human
adenovirus type 2, foot-and-mouth disease virus, echovirus 9, and
human paraechovirus 1 [78–82]; aVb3 and aIIbb3 bind hantavirus
[76]; a2b1 interacts with human echovirus 1 and rotavirus [83,84].
LASV and most isolates of the Old World arenaviruses use a-
dystroglycan (a-DG) [85,86]. By using this receptor, those viruses
can infect endothelial cells without cytotoxicity. However, as a
result of interactions with virus particles or virus-infected cells,
platelets will be activated to adhere to endothelial cells, thereby
reducing the number of circulating platelets, altering endothelial
cell function, and increasing vascular permeability.
There are other viral receptors that are present in cells of the
immune system, such as Clec-2 and DC-SIGN that binds HIV
[68,87]; DC-SIGN also shows affinity for other lentiviruses and
DENV [88,89]. DC-SIGN, Axl, and Tyro3 are Ebola virus and
LASV receptors [90–93]. Ebola virus requires the cholesterol
transporter Niemann-Pick C1 (NPC1) for cell entry [94]. This
receptor is found in cells that are affected by HFV, such as
gastrointestinal epithelial cells, and hepatocytes. Although all these
receptors that bind HFV in target cells are also present in platelets
and MKs (and, in some cases, have been shown to mediate virus
internalization), it remains unknown whether they interact with
platelets in vivo or if virus internalization leads to successful
replication or even propagation of these viruses.
After binding viruses, platelets can engulf them and process
them in small endocytic vesicles that are later fused with secretory
granules that destroy the virus [61,67,95]. However, virus
destruction is not always successful, and infected platelets can
contribute to the dissemination of an infection [68] and to platelet
dysfunction, as seen in HFRS [96].
Immunological Destruction of Platelets or Their
Precursor Cells
There are at least three different ways in which the immune
system can contribute to the reduction of platelet numbers
(Figure 4). The first one is platelet sequestration by macrophages
at the infection site and/or in the spleen. Viral activation of
platelets induces an increased expression of P-selectin that
Figure 2. Platelet structure. Platelets have multiple surface receptors, a cannalicular system, microtubules, mitochondria, three types of granules
(lysosomal, alpha, and dense), and deposits of small factors like glycogen (Figure 2 and 3) [54]. Whereas dense granules contain factors that
potentiate platelet activation, a-granules contain growth factors and clotting proteins that contribute to hemostasis [130].
doi:10.1371/journal.pntd.0002858.g002
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functions as a receptor for macrophages [68]. As seen in SFTSV,
another member of the Bunyaviridae associated with coagulation
disorders, binding to platelets induces macrophage phagocytosis of
platelets in the spleen, causing a decrease in circulating platelet
numbers [97].
A second mechanism of platelet depletion is platelet-leukocyte
aggregation and subsequent phagocytosis by macrophages. Acti-
vated platelets recruit leukocytes to inflamed endothelium, and
neutrophils are the most frequent and rapidly recruited cells to the
site of injury or inflammation [98,99]. Platelet-leukocyte interac-
tion is mediated by the platelet GPIba protein and the leukocyte
macrophage-1 antigen protein (MAC-1), also known as aMb2
integrin, complement receptor 3 (CR3) protein, CD11B, and
Integrin alpha-M (ITGAM). The mRNA for this integrin is 4-fold
up-regulated in peripheral blood mononuclear cells (PBMC)
exposed to LASV in comparison to PBMC exposed to a benign
virus, ML29 [100]. ML29 is a nonpathogenic reassortant between
Lassa and Mopeia viruses, with the L genome segment from
Mopeia and the S segment from LASV. It is tempting to speculate
that the up-regulation of this integrin on leukocytes promotes their
aggregation with platelets and has a role in LASV pathogenesis,
but many more studies are needed.
Platelets secrete chemokine proteins, such as CXCL1, CXCL4
(PF4), CXCL4L, CCL5, CXCL7, CXCL8 (IL-8), CXCL12,
CXCR2, CCL2, CCL3, and CCL5, that promote angiogenesis and
chemotaxis [101]. CXCL4 and CCL5 specifically induce monocyte
migration and binding to the inflamed endothelium [102]. In a
similar way, crosslinking of P-selectin glycoprotein ligand 1 (PSGL-
1) on monocytes by P-selectin expressed in platelets and endothelial
cells enhances monocyte recruitment to the activated endothelium
[101] as seen in adenovirus or DENV-endothelial infected cells
[77,103]. This cascade of interactions not only regulates leukocyte
trafficking to the inflamed site but also increases local platelet
sequestration, phagocytosis and lysis.
A third mechanism of platelet depletion is their destruction
mediated by platelet-virus associated antibodies. In a secondary
DENV infection, antibodies against the prM viral protein facilitate
efficient binding of immature particles to Fc-receptor-expressing
cells [104]. Platelets express FccRIIa, which binds these anti-prM-
DENV complexes and renders them suceptible to destruction by
the immune system. In addition, platelet-DENV complexes also
bind the C3-complement molecule and platelet-associated IgM or
IgG antibodies, targeting them for clearance by cells of the
immune system [105,106]. Furthermore, DENV antibodies
reacting against platelet glycoproteins can mediate destruction of
platelets by complement or by the monocyte-macrophage system.
Such antibodies could also suppress MK proliferation and
maturation. Specifically, IgM anti-platelet autoantibodies not only
induce platelet lysis via complement activation but also inhibit
ADP-induced platelet aggregation [107].
Figure 3. Platelet content. Membrane glycoproteins of platelets include GPIa, GPIIb/IIIa (aIIbb3), or VLA-5 (fibrinogen receptor); GPIb/IX/V (vW and
Mac-1 receptor); GPIc’-IIa or VLA-6 (laminin receptor); and a2b1 GPVI (Collagen receptor). Alpha granules contain P-selectin; platelet factor 4;
transforming factor-b1; chemokines; proteoglycan; platelet-derived growth factor; a2-plasmin inhibitor; vitronectin; laminin; CD63; TGFbeta; CLEC-2;
thrombospondin; fibronectin; B-thromboglobulin; vWF; fibrinogen; coagulation factors V, XI, and XIII; integrins; thrombocidins; proteases; thrombin;
prothrombin; kininogens; immunoglobulin family receptors; leucine-rich repeat family receptors; and other proinflammatory and immune-
modulating factors. Dense granules hold ADP, ATP, calcium, serotonin, histamine, dopamine, phosphate, eicosanoids. Receptors for primary
agonist include P2X, P2Y1, and P2Y12 (ADP); TPa-R and TPb-R (TXA2); PAR-1 and PAR-4 (thrombin); PAFR (platelet-activating factor); 5-HT2A
(Serotonine); epinephrine receptors (catecholamines); Fc and complement C3a/C5a receptors; and TLRs, CD40, CD40L, ICAM-2, DC-SIGN, JAM-A, and
FccRII. Between the platelet Metabolites are TXA2, sphingosine-1-phopate, PAF, glycogen, platelet factor 4 (PF-4), RANTES, connective tissue
activating peptide 3 (CTAP-3), platelet basic protein, thymosin b-4 (Tb-4), fibrinopeptide B (FP-B), and fibrinopeptide A (FP-A).
doi:10.1371/journal.pntd.0002858.g003
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Suppression of Megakaryocyte and Platelet
Development
Several viruses, like HIV-1, HCV, and human CMV, are able to
replicate in MKs, and those infections are associated with
thrombocytopenia and other thrombotic disorders [108–110]. Since
platelets are derived from MKs, they express similar membrane
receptors, therefore platelets may bind and internalize similar viruses.
However, there are also differences in receptor expression and
metabolic pathways among MK-precursors, mature MKs, and
platelets that make them susceptible or resistant to specific viral
infections. For instance, immature MKs express CD4 antigen on
their surface, making them susceptible to HIV infection, while mature
MKs and platelets do not express CD4 [68]. HHV-7 has the capacity
to infect CD61+ megakaryoblast cells, increasing apoptosis of these
cells and causing an impaired megakaryopoiesis [111]. Furthermore,
HHV-6 is able to infect CD34+ hematopoietic progenitors cells,
thereby suppressing thrombopoiesis [112]. DENV decreases platelet
numbers by inhibiting progenitor cell development in the bone
marrow. In vitro, early blast and hematopoietic cells in an
intermediate state of differentiation were abortively infected, killed,
and eliminated by DC phagocytosis [113]. Pathogenic hantaviruses
can infect MKs, in contrast to non-pathogenic hantaviruses. HTNV-
infected MKs show no increased apoptosis or problems with
differentiation, but they do show increased surface expression of
HLA, making them good CTL targets and resulting in acute
thrombocytopenia [114]. It has also been proposed that LCMV-
induced thrombocytopenia in mouse is associated with the effect of
IFN-a/b on MKs, leading to the generation of altered platelets [115].
Another mechanism that affects platelet formation is the
decreased production of thrombopoietin (TPO) due to liver
damage in HCV infection that results in suppression of
development in the bone marrow [116].
Inhibition of Platelet Function
The integrin b3 (ITGB3 or CD61+) subunit in platelets can
combine with different partners, resulting in different integrin
receptors with multiple functions. The integrin avb3 is a receptor
for cytotactin, fibronectin, laminin, matrix metalloproteinase-2,
osteopontin, osteomodulin, prothrombin, thrombospondin, vitro-
nectin, and von Willebrand factor. Integrin aIIbb3 is a receptor for
fibronectin, fibrinogen, plasminogen, prothrombin, thrombospon-
din, and vitronectin. It mediates platelet–platelet interaction by
binding of soluble fibrinogen. In acute DENV infection there is an
increase in CD61+ on platelets and MKs containing viral proteins
and RNA that suggests a link with platelet dysfunction and low
platelet counts [105].
Arenaviruses have several mechanisms for inhibiting platelet
function. In the LCMV-infected mouse model for thrombocyto-
penia, ITGB32/2 mice developed a severe hemorrhagic anemia
after infection, even with normal platelet counts, suggesting a key
role of ITGB3 in protecting against bleeding [115]. In vitro
exposure of human PBMC to a pathogenic arenavirus (LASV)
increases the expression of ITGB3 mRNA by 12-fold in contrast to
ML29, the attenuated derivative of LASV mentioned earlier, that
does not affect ITGB3 mRNA expression [100]. How LASV is
affecting the function of ITGB3 in vivo remains to be explored,
and the protection seen in the mouse model, combined with the
increased expression in human PBMC exposed to a pathogenic
virus, suggests that ITGB3 is playing an important role in
arenavirus infections.
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aDestruction of platelets by direct interaction: HFV can bind platelets directly causing activation and granule release.
bImmunological destruction of platelet-virus complexes: Thrombocytopenia can be mediated by macrophages sequestration of platelet-virus complexes at the infection
site or/and in the spleen, platelets-virus-leukocyte aggregation and subsequent phagocytosis by macrophages or destruction mediated by platelet-virus associated
antibodies.
cMegakaryocytes or Megakaryocyte precursors impairment: HFV can infect megakaryocytes or their precursor causing reduction in platelets number or impairment in
their function.
dInhibition of platelet function: Some unidentified soluble factors present in plasma from infected patients can inhibit aggregation of platelets from healthy individuals.
doi:10.1371/journal.pntd.0002858.t004
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Figure 4. Immunological destruction of platelets. Platelets can interact with macrophages and neutrophils at the infection site and/or in the
spleen through immuno-complexes or directly by cellular-ligand interactions. These interactions lead to either platelet sequestration or platelet
destruction mediated by the immune system.
doi:10.1371/journal.pntd.0002858.g004
Key Learning Points
N Viral hemorrhagic fevers (VHF) are a group of zoonotic
diseases characterized by fever and bleeding disorders
that can progress to shock and death.
N Thrombocytopenia (reduction of platelet numbers) and
depressed immune responses are hallmarks of VHF;
platelets are involved in both processes, and their
function is also compromised in these types of
infections.
N Platelet–HFV interactions are poorly understood and
seem to be different in each disease, but some
mechanisms are common to all VHF pathogenesis.
N It is important to understand the role of platelets in each
viral hemorrhagic fever disease to understand the
pathogenesis mechanisms and identify new possible
ways to prevent or treat this group of diseases.
Five Key Papers in the Field
1. Yeaman MR (1997) The role of platelets in antimicrobial
host defense. Clin Infect Dis 25: 951–968; quiz 969–970.
2. George JN (2000) Platelets. Lancet 355: 1531–1539.
3. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM
(2002) Host defense role of platelets: engulfment of HIV
and Staphylococcus aureus occurs in a specific subcel-
lular compartment and is enhanced by platelet activa-
tion. Blood 99: 4021–4029.
4. Patel SR, Richardson JL, Schulze H, Kahle E, Galjart N, et al.
(2005) Differential roles of microtubule assembly and
sliding in proplatelet formation by megakaryocytes.
Blood 106: 4076–4085.
5. Loria GD, Romagnoli PA, Moseley NB, Rucavado A,
Altman JD (2013) Platelets support a protective immune
response to LCMV by preventing splenic necrosis. Blood
121: 940–950.
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It is noteworthy that there are important differences between
the LCMV mouse model for thrombocytopenia, in which IFN-a/
b mediates the decrease in platelet numbers, platelet dysfunction,
and bleeding, and the LCMV primate model, in which the IFN-a/
b expression is not remarkable and yet there are bleeding signs
[117–119]. Similarly, LCMV infection in humans more closely
resembles a JUNV infection, with marked thrombocytopenia and
platelet dysfunction [115], than a LASV infection, which is
characterized by variable changes in platelet numbers and
constant compromise of platelet function. IFN-a/b is affecting
platelets either by a direct effect on MKs, leading to the
production of altered platelets, or by the up-regulation of
endothelial cell-derived platelet inhibitors, such as nitric oxide
and prostacyclin, that indirectly contribute to the observed platelet
dysfunction [115]. In vitro infections of MKs with JUNV showed
impaired thrombopoiesis by decreasing pro-platelet formation,
platelet release, and P-selectin externalization via a bystander
effect. All these effects were associated with increased levels of type
I IFN [120]. In addition, endothelial cells infected with a
pathogenic JUNV strain showed an increase in nitric oxide
(NO), endothelial nitric oxide synthase (eNOS), and PGI2
production [121]. Similarly, Pichinde virus (PICV, another
arenavirus) induces endothelial cell permeability through the
production of NO [122]. It is expected that the up-regulation of
NO by JUNV will have similar effects on the permeability of
endothelial cell layers.
It has been demonstrated that thrombomodulin (THBD) binds
thrombin and blocks the ability of thrombin to activate platelets.
THBD also completely blocked tissue factor-induced microparticle
formation [123–124]. Additionally, platelets contain functional
THBD [125], and the platelet alpha-granule protein PF4 enhances
activated protein C (APC) generation by soluble and membrane
THBD in endothelial cells [126]. PBMC exposed to a pathogenic
arenavirus (LASV) increased expression of THBD mRNA by 14-
fold. In contrast, the attenuated ML29 inhibits THBD mRNA
expression. This pattern was observed also at the protein level in
PBMC and DC for both soluble and membrane-bound THBD
[100]. Serum from LASV-infected patients suffering hemorrhagic
symptoms contains an unidentified soluble factor able to inhibit
aggregation of platelets from healthy individuals [127]. Similarly,
there is evidence of an inhibitor in plasma of JUNV-infected
patients [128] that is not neutralized by plasma containing high
titers of protective antibodies against JUNV [129], suggesting that
this is not a virus-derived molecule. This factor could be THBD
that, after an overexpression induced by LASV, inhibits platelet
activation through thrombin binding and, at the same time,
prevents thrombin production by APC. As a consequence, there is
an increased susceptibility to hemorrhagic episodes during LF
disease [100].
In conclusion, HFVs all induce homeostatic abnormalities,
inhibit the antiviral immune response, and display high levels of
viremia. Platelets are peripheral blood elements that play roles in
both homeostasis and inflammation. Platelet–HFV interactions
are poorly understood and seem to be different in each disease, but
there are similar mechanisms underlying all VHF pathogenesis.
The identification of such mechanisms can lead to the develop-
ment of new treatment options for this group of diseases that kill
millions of human beings each year.
References
1. Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and
challenges. Nat Med 10: S110–S121.
2. Bray M (2005) Pathogenesis of viral hemorrhagic fever. Curr Opin Immunol
17: 399–403.
3. Lukashevich IS, Maryankova R, Vladyko AS, Nashkevich N, Koleda S, et al.
(1999) Lassa and Mopeia virus replication in human monocytes/macrophages
and in endothelial cells: different effects on IL-8 and TNF-alpha gene
expression. J Med Virol 59: 552–560.
4. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, et al. (2003)
Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola
and Lassa viruses. J Immunol 170: 2797–2801.
5. Macal M, Lewis GM, Kunz S, Flavell R, Harker JA, et al. (2012) Plasmacytoid
dendritic cells are productively infected and activated through TLR-7 early
after arenavirus infection. Cell Host Microbe 11: 617–630.
6. Fang S, Wu Y, Wu N, Zhang J, An J (2013) Recent advances in DENV
receptors. ScientificWorldJournal 2013: 684690.
7. Gommet C, Billecocq A, Jouvion G, Hasan M, Zaverucha do Valle T, et al.
(2011) Tissue tropism and target cells of NSs-deleted rift valley fever virus in
live immunodeficient mice. PLoS Negl Trop Dis 5: e1421.
8. Peyrefitte CN, Perret M, Garcia S, Rodrigues R, Bagnaud A, et al. (2010)
Differential activation profiles of Crimean-Congo hemorrhagic fever virus- and
Dugbe virus-infected antigen-presenting cells. J Gen Virol 91: 189–198.
9. La Ruche G, Souares Y, Armengaud A, Peloux-Petiot F, Delaunay P, et al.
(2010) First two autochthonous dengue virus infections in metropolitan France,
September 2010. Euro Surveill 15: 19676.
10. Kurolt IC, Betica-Radic L, Dakovic-Rode O, Franco L, Zelena H, et al. (2013)
Molecular characterization of dengue virus 1 from autochthonous dengue fever
cases in Croatia. Clin Microbiol Infect 19: E163–165.
11. WHO (2012) Outbreak news. Dengue fever in Madeira,Portugal. Wkly
Epidemiol Rec 87: 413.
12. Radke EG, Gregory CJ, Kintziger KW, Sauber-Schatz EK, Hunsperger EA, et
al. (2012) Dengue outbreak in Key West, Florida, USA, 2009. Emerg Infect Dis
18: 135–137.
13. Kouri GP, Guzman MG, Bravo JR, Triana C (1989) Dengue haemorrhagic
fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull
World Health Organ 67: 375–380.
14. Barrett AD, Higgs S (2007) Yellow fever: a disease that has yet to be conquered.
Annu Rev Entomol 52: 209–229.
15. WHO (2011) Yellow fever. Fact sheet No. 100. Available: http://www.who.
int/mediacentre/factsheets/fs100/en/. Accessed 13 May 2014.
16. Mehla R, Kumar SR, Yadav P, Barde PV, Yergolkar PN, et al. (2009) Recent
ancestry of Kyasanur Forest disease virus. Emerg Infect Dis 15: 1431–1437.
17. Madani TA (2005) Alkhumra virus infection, a new viral hemorrhagic fever in
Saudi Arabia. J Infect 51: 91–97.
18. Dodd KA, Bird BH, Khristova ML, Albarino CG, Carroll SA, et al. (2011)
Ancient ancestry of KFDV and AHFV revealed by complete genome analyses
of viruses isolated from ticks and mammalian hosts. PLoS Negl Trop Dis 5:
e1352.
19. Richmond JK, Baglole DJ (2003) Lassa fever: epidemiology, clinical features,
and social consequences. BMJ 327: 1271–1275.
20. Asogun DA, Adomeh DI, Ehimuan J, Odia I, Hass M, et al. (2012) Molecular
diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons
learnt from two years of laboratory operation. PLoS Negl Trop Dis 6: e1839.
21. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, et al. (2009)
Genetic detection and characterization of Lujo virus, a new hemorrhagic
fever-associated arenavirus from southern Africa. PLoS Pathog 5:
e1000455.
22. Maiztegui JI (1975) Clinical and epidemiological patterns of Argentine
haemorrhagic fever. Bull World Health Organ 52: 567–575.
23. Maiztegui JI, McKee KT, Jr., Barrera Oro JG, Harrison LH, Gibbs PH, et al.
(1998) Protective efficacy of a live attenuated vaccine against Argentine
hemorrhagic fever. AHF Study Group. J Infect Dis 177: 277–283.
24. ProMED (2012) Bolivian Hemorrhagic Fever. Available: http://www.
promedmail.org/direct.php?id = 20120730.1220842. Accessed 13 May 2014.
25. Fulhorst CF, Cajimat MN, Milazzo ML, Paredes H, de Manzione NM, et al.
(2008) Genetic diversity between and within the arenavirus species indigenous
to western Venezuela. Virology 378: 205–213.
26. The Travel Doctor (2012) Outbreak of Venezuelan hemorrhagic fever (VHF).
Available: http://www.thetraveldoctor.com/alert_view.php?alertsid = 207&country
= Venezuela. Accessed 13 May 2014.
27. Bi Z, Formenty PB, Roth CE (2008) Hantavirus infection: a review and global
update. J Infect Dev Ctries 2: 3–23.
28. Klempa B, Tkachenko EA, Dzagurova TK, Yunicheva YV, Morozov VG,
et al. (2008) Hemorrhagic fever with renal syndrome caused by 2 lineages of
Dobrava hantavirus, Russia. Emerg Infect Dis 14: 617–625.
29. Krautkramer E, Zeier M, Plyusnin A (2013) Hantavirus infection: an emerging
infectious disease causing acute renal failure. Kidney Int 83: 23–27.
30. Ergonul O (2006) Crimean-Congo haemorrhagic fever. Lancet Infect Dis 6:
203–214.
31. PRESSTV (2009) Congo-Crimean fever proves deadly in Iran. Available:
http://edition.presstv.ir/detail/105532.html. Accessed 13 May 2014.
32. Shoemaker T, Boulianne C, Vincent MJ, Pezzanite L, Al-Qahtani MM, et al.
(2002) Genetic analysis of viruses associated with emergence of Rift Valley fever
in Saudi Arabia and Yemen, 2000–01. Emerg Infect Dis 8: 1415–1420.
PLOS Neglected Tropical Diseases | www.plosntds.org 10 June 2014 | Volume 8 | Issue 6 | e2858
33. Nicolas G, Durand B, Duboz R, Rakotondravao R, Chevalier V (2013)
Description and analysis of the cattle trade network in the Madagascar
highlands: potential role in the diffusion of Rift Valley fever virus. Acta Trop
126: 19–27.
34. Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, et al. (2011) Fever with
thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med
364: 1523–1532.
35. ProMED (2013) Severe Fever with Thrombocytopenia Syndrome - Japan. 2005
Fatality. Available: http://www.promedmail.org/direct.php?id = 20130227.
1562954. Accessed 13 May 2014.
36. Kim KH, Yi J, Kim G, Choi SJ, Jun KI, et al. (2013) Severe fever with
thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis 19: 1892–
1894.
37. Bao CJ, Guo XL, Qi X, Hu JL, Zhou MH, et al. (2011) A family cluster of
infections by a newly recognized bunyavirus in eastern China, 2007: further
evidence of person-to-person transmission. Clin Infect Dis 53: 1208–1214.
38. Leroy EM, Gonzalez JP, Baize S (2011) Ebola and Marburg haemorrhagic
fever viruses: major scientific advances, but a relatively minor public health
threat for Africa. Clin Microbiol Infect 17: 964–976.
39. WHO (2012) Marburg haemorrhagic fever in Uganda - update. Accessed:
http://www.who.int/csr/don/2012_10_31/en/. Accessed 13 May 2014.
40. Towner JS, Pourrut X, Albarino CG, Nkogue CN, Bird BH, et al. (2007)
Marburg virus infection detected in a common African bat. PLoS ONE 2:
e764.
41. Khan SH, Goba A, Chu M, Roth C, Healing T, et al. (2008) New
opportunities for field research on the pathogenesis and treatment of Lassa
fever. Antiviral Res 78: 103–115.
42. Gould EA, Solomon T (2008) Pathogenic flaviviruses. Lancet 371: 500–509.
43. Gardner CL, Ryman KD (2010) Yellow fever: a reemerging threat. Clin Lab
Med 30: 237–260.
44. Kortepeter MG, Bausch DG, Bray M (2011) Basic clinical and laboratory
features of filoviral hemorrhagic fever. J Infect Dis 204 Suppl 3: S810–816.
45. Ranjit S, Kissoon N (2011) Dengue hemorrhagic fever and shock syndromes.
Pediatr Crit Care Med 12: 90–100.
46. Deng B, Zhang S, Geng Y, Zhang Y, Wang Y, et al. (2012) Cytokine and
chemokine levels in patients with severe fever with thrombocytopenia
syndrome virus. PLoS ONE 7: e41365.
47. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, et al. (1996)
Filovirus-induced endothelial leakage triggered by infected monocytes/
macrophages. J Virol 70: 2208–2214.
48. Gupta M, Mahanty S, Ahmed R, Rollin PE (2001) Monocyte-derived human
macrophages and peripheral blood mononuclear cells infected with ebola virus
secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in
vitro. Virology 284: 20–25.
49. Fennewald SM, Aronson JF, Zhang L, Herzog NK (2002) Alterations in NF-
kappaB and RBP-Jkappa by arenavirus infection of macrophages in vitro and
in vivo. J Virol 76: 1154–1162.
50. McElroy AK, Nichol ST (2012) Rift Valley fever virus inhibits a pro-
inflammatory response in experimentally infected human monocyte derived
macrophages and a pro-inflammatory cytokine response may be associated
with patient survival during natural infection. Virology 422: 6–12.
51. Stroher U, West E, Bugany H, Klenk HD, Schnittler HJ, et al. (2001) Infection
and activation of monocytes by Marburg and Ebola viruses. J Virol 75: 11025–
11033.
52. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, et al.
(2002) Inflammatory responses in Ebola virus-infected patients. Clin Exp
Immunol 128: 163–168.
53. Patel SR, Richardson JL, Schulze H, Kahle E, Galjart N, et al. (2005)
Differential roles of microtubule assembly and sliding in proplatelet formation
by megakaryocytes. Blood 106: 4076–4085.
54. George JN (2000) Platelets. Lancet 355: 1531–1539.
55. Kerrigan SW, Cox D (2010) Platelet-bacterial interactions. Cell Mol Life Sci
67: 513–523.
56. Yeaman MR (1997) The role of platelets in antimicrobial host defense. Clin
Infect Dis 25: 951–968; quiz 969–970.
57. Beaulieu LM, Freedman JE (2010) The role of inflammation in regulating
platelet production and function: Toll-like receptors in platelets and
megakaryocytes. Thromb Res 125: 205–209.
58. Tang YQ, Yeaman MR, Selsted ME (2002) Antimicrobial peptides from
human platelets. Infect Immun 70: 6524–6533.
59. Kalvegren H, Majeed M, Bengtsson T (2003) Chlamydia pneumoniae binds to
platelets and triggers P-selectin expression and aggregation: a causal role in
cardiovascular disease? Arterioscler Thromb Vasc Biol 23: 1677–1683.
60. Bertling A, Niemann S, Uekotter A, Fegeler W, Lass-Florl C, et al. (2010)
Candida albicans and its metabolite gliotoxin inhibit platelet function via
interaction with thiols. Thromb Haemost 104: 270–278.
61. Danon D, Jerushalmy Z, De Vries A (1959) Incorporation of influenza virus in
human blood platelets in vitro. Electron microscopical observation. Virology 9:
719–722.
62. Jerushalmy Z, Kohn A, De Vries A (1961) Interaction of myxoviruses with
human blood platelets in vitro. Proc Soc Exp Biol Med 106: 462–466.
63. De Harven E, Friend C (1960) Further electron microscope studies of a mouse
leukemia induced by cell-free filtrates. J Biophys Biochem Cytol 7: 747–752.
64. Brown WM, Axelrad AA (1976) Effect of Friend leukemia virus on
megakaryocytes and platelets in mice. Int J Cancer 18: 764–773.
65. Bik T, Sarov I, Livne A (1982) Interaction between vaccinia virus and human
blood platelets. Blood 59: 482–487.
66. Zucker-Franklin D, Cao YZ (1989) Megakaryocytes of human immunodefi-
ciency virus-infected individuals express viral RNA. Proc Natl Acad Sci U S A
86: 5595–5599.
67. Zucker-Franklin D, Seremetis S, Zheng ZY (1990) Internalization of human
immunodeficiency virus type I and other retroviruses by megakaryocytes and
platelets. Blood 75: 1920–1923.
68. Flaujac C, Boukour S, Cramer-Borde E (2010) Platelets and viruses: an
ambivalent relationship. Cell Mol Life Sci 67: 545–556.
69. McKay DG, Margaretten W (1967) Disseminated intravascular coagulation in
virus diseases. Arch Intern Med 120: 129–152.
70. Niewold TB, Bundrick JB (2006) Disseminated intravascular coagulation due to
cytomegalovirus infection in an immunocompetent adult treated with plasma
exchange. Am J Hematol 81: 454–457.
71. Limbos MA, Lieberman JM (1996) Disseminated intravascular coagulation
associated with rotavirus gastroenteritis: report of two cases. Clin Infect Dis 22:
834–836.
72. Shimony N, Elkin G, Kolodkin-Gal D, Krasny L, Urieli-Shoval S, et al. (2009)
Analysis of adenoviral attachment to human platelets. Virol J 6: 25.
73. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, et al. (2006) Platelet Toll-
like receptor expression modulates lipopolysaccharide-induced thrombocyto-
penia and tumor necrosis factor-alpha production in vivo. Blood 107: 637–641.
74. Gavrilovskaya IN, Gorbunova EE, Mackow ER (2010) Pathogenic hantavi-
ruses direct the adherence of quiescent platelets to infected endothelial cells.
J Virol 84: 4832–4839.
75. Blair P, Rex S, Vitseva O, Beaulieu L, Tanriverdi K, et al. (2009) Stimulation
of Toll-like receptor 2 in human platelets induces a thromboinflammatory
response through activation of phosphoinositide 3-kinase. Circ Res 104: 346–
354.
76. Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER (1999) Cellular entry
of hantaviruses which cause hemorrhagic fever with renal syndrome is
mediated by beta3 integrins. J Virol 73: 3951–3959.
77. Krishnamurti C, Peat RA, Cutting MA, Rothwell SW (2002) Platelet adhesion
to dengue-2 virus-infected endothelial cells. Am J Trop Med Hyg 66: 435–441.
78. Roivainen M, Hyypia T, Piirainen L, Kalkkinen N, Stanway G, et al. (1991)
RGD-dependent entry of coxsackievirus A9 into host cells and its bypass after
cleavage of VP1 protein by intestinal proteases. J Virol 65: 4735–4740.
79. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins alpha v
beta 3 and alpha v beta 5 promote adenovirus internalization but not virus
attachment. Cell 73: 309–319.
80. Berinstein A, Roivainen M, Hovi T, Mason PW, Baxt B (1995) Antibodies to
the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection
of foot-and-mouth disease virus to cultured cells. J Virol 69: 2664–2666.
81. Nelsen-Salz B, Eggers HJ, Zimmermann H (1999) Integrin alpha(v)beta3
(vitronectin receptor) is a candidate receptor for the virulent echovirus 9 strain
Barty. J Gen Virol 80 (Pt 9): 2311–2313.
82. Triantafilou K, Triantafilou M, Takada Y, Fernandez N (2000) Human
parechovirus 1 utilizes integrins alphavbeta3 and alphavbeta1 as receptors.
J Virol 74: 5856–5862.
83. Fleming FE, Graham KL, Takada Y, Coulson BS (2011) Determinants of the
specificity of rotavirus interactions with the alpha2beta1 integrin. J Biol Chem
286: 6165–6174.
84. Bergelson JM, St John NF, Kawaguchi S, Pasqualini R, Berdichevsky F, et al.
(1994) The I domain is essential for echovirus 1 interaction with VLA-2. Cell
Adhes Commun 2: 455–464.
85. Cao W, Henry MD, Borrow P, Yamada H, Elder JH, et al. (1998)
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomen-
ingitis virus and Lassa fever virus. Science 282: 2079–2081.
86. Kunz S, Rojek JM, Perez M, Spiropoulou CF, Oldstone MB (2005)
Characterization of the interaction of lassa fever virus with its cellular receptor
alpha-dystroglycan. J Virol 79: 5979–5987.
87. Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, et al. (2006)
DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1
capture by platelets. J Virol 80: 8951–8960.
88. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J,
et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human
dendritic cells. J Exp Med 197: 823–829.
89. Curtis BM, Scharnowske S, Watson AJ (1992) Sequence and expression of a
membrane-associated C-type lectin that exhibits CD4-independent binding of
human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad
Sci U S A 89: 8356–8360.
90. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, et al. (2002) C-type
lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and
in trans. J Virol 76: 6841–6844.
91. Shimojima M, Ikeda Y, Kawaoka Y (2007) The mechanism of Axl-mediated
Ebola virus infection. J Infect Dis 196 Suppl 2: S259–263.
92. Hunt CL, Kolokoltsov AA, Davey RA, Maury W (2011) The Tyro3 receptor
kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol 85: 334–347.
93. Shimojima M, Stroher U, Ebihara H, Feldmann H, Kawaoka Y (2012)
Identification of cell surface molecules involved in dystroglycan-independent
Lassa virus cell entry. J Virol 86: 2067–2078.
PLOS Neglected Tropical Diseases | www.plosntds.org 11 June 2014 | Volume 8 | Issue 6 | e2858
94. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, et al. (2011)
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1.
Nature 477: 340–343.
95. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM (2002) Host
defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs
in a specific subcellular compartment and is enhanced by platelet activation.
Blood 99: 4021–4029.
96. Cosgriff TM, Lee HW, See AF, Parrish DB, Moon JS, et al. (1991) Platelet
dysfunction contributes to the haemostatic defect in haemorrhagic fever with
renal syndrome. Trans R Soc Trop Med Hyg 85: 660–663.
97. Jin C, Liang M, Ning J, Gu W, Jiang H, et al. (2012) Pathogenesis of emerging
severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model.
Proc Natl Acad Sci U S A 109: 10053–10058.
98. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA (1996)
Neutrophil rolling, arrest, and transmigration across activated, surface-
adherent platelets via sequential action of P-selectin and the beta 2-integrin
CD11b/CD18. Blood 88: 146–157.
99. Ghasemzadeh M, Hosseini E (2013) Platelet-leukocyte crosstalk: Linking
proinflammatory responses to procoagulant state. Thromb Res 131: 191–197.
100. Zapata JC, Carrion R Jr, Patterson JL, Crasta O, Zhang Y, et al. (2013)
Transcriptome Analysis of Human Peripheral Blood Mononuclear Cells
Exposed to Lassa Virus and to the Attenuated Mopeia/Lassa Reassortant 29
(ML29), a Vaccine Candidate. PLoS Negl Trop Dis 7: e2406.
101. von Hundelshausen P, Petersen F, Brandt E (2007) Platelet-derived chemokines
in vascular biology. Thromb Haemost 97: 704–713.
102. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, et al.
(2001) RANTES deposition by platelets triggers monocyte arrest on inflamed
and atherosclerotic endothelium. Circulation 103: 1772–1777.
103. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D (2007)
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor
and P-selectin in mediating accelerated platelet clearance. Blood 109: 2832–
2839.
104. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der
Ende-Metselaar H, Lei HY, et al. (2010) Immature dengue virus: a veiled
pathogen? PLoS Pathog 6: e1000718.
105. Noisakran S, Onlamoon N, Pattanapanyasat K, Hsiao HM, Songprakhon P, et
al. (2012) Role of CD61+ cells in thrombocytopenia of dengue patients.
Int J Hematol 96: 600–610.
106. Saito M, Oishi K, Inoue S, Dimaano EM, Alera MT, et al. (2004) Association
of increased platelet-associated immunoglobulins with thrombocytopenia and
the severity of disease in secondary dengue virus infections. Clin Exp Immunol
138: 299–303.
107. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, et al. (2001) Generation of IgM
anti-platelet autoantibody in dengue patients. J Med Virol 63: 143–149.
108. Chelucci C, Federico M, Guerriero R, Mattia G, Casella I, et al. (1998)
Productive human immunodeficiency virus-1 infection of purified megakaryo-
cytic progenitors/precursors and maturing megakaryocytes. Blood 91: 1225–
1234.
109. Li X, Jeffers LJ, Garon C, Fischer ER, Scheffel J, et al. (1999) Persistence of
hepatitis C virus in a human megakaryoblastic leukaemia cell line. J Viral
Hepat 6: 107–114.
110. Crapnell K, Zanjani ED, Chaudhuri A, Ascensao JL, St Jeor S, et al. (2000) In
vitro infection of megakaryocytes and their precursors by human cytomega-
lovirus. Blood 95: 487–493.
111. Gonelli A, Mirandola P, Grill V, Secchiero P, Zauli G (2002) Human
herpesvirus 7 infection impairs the survival/differentiation of megakaryocytic
cells. Haematologica 87: 1223–1225.
112. Isomura H, Yoshida M, Namba H, Fujiwara N, Ohuchi R, et al. (2000)
Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible
megakaryocytic colony formation in vitro. J Gen Virol 81: 663–673.
113. La Russa VF, Innis BL (1995) Mechanisms of dengue virus-induced bone
marrow suppression. Baillieres Clin Haematol 8: 249–270.
114. Lutteke N, Raftery MJ, Lalwani P, Lee MH, Giese T, et al. (2010) Switch to
high-level virus replication and HLA class I upregulation in differentiating
megakaryocytic cells after infection with pathogenic hantavirus. Virology 405:
70–80.
115. Iannacone M, Sitia G, Isogawa M, Whitmire JK, Marchese P, et al. (2008)
Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-
dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad
Sci U S A 105: 629–634.
116. Weksler BB (2007) Review article: the pathophysiology of thrombocytopenia in
hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther
26 Suppl 1: 13–19.
117. Binder D, Fehr J, Hengartner H, Zinkernagel RM (1997) Virus-induced
transient bone marrow aplasia: major role of interferon-alpha/beta during
acute infection with the noncytopathic lymphocytic choriomeningitis virus.
J Exp Med 185: 517–530.
118. Loria GD, Romagnoli PA, Moseley NB, Rucavado A, Altman JD (2013)
Platelets support a protective immune response to LCMV by preventing splenic
necrosis. Blood 121: 940–950.
119. Zapata JC, Pauza CD, Djavani MM, Rodas JD, Moshkoff D, et al. (2011)
Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model
for Lassa fever. Antiviral Res 92: 125–138.
120. Pozner RG, Ure AE, Jaquenod de Giusti C, D’Atri LP, Italiano JE, et al. (2010)
Junin virus infection of human hematopoietic progenitors impairs in vitro
proplatelet formation and platelet release via a bystander effect involving type I
IFN signaling. PLoS Pathog 6: e1000847.
121. Gomez RM, Pozner RG, Lazzari MA, D’Atri LP, Negrotto S, et al. (2003)
Endothelial cell function alteration after Junin virus infection. Thromb
Haemost 90: 326–333.
122. Brocato RL, Voss TG (2009) Pichinde virus induces microvascular endothelial
cell permeability through the production of nitric oxide. Virol J 6: 162.
123. Esmon NL, Carroll RC, Esmon CT (1983) Thrombomodulin blocks the ability
of thrombin to activate platelets. J Biol Chem 258: 12238–12242.
124. Cafer Adiguzel, Omer Iqbal, Daniel Fareed, Debra Hoppensteadt, Walter
Jeske MS, et al. (2008) Modulation of Platelet Function by Recombinant
Thrombomodulin Hematologic Implications. The FASEB Journal 22 (Meeting
Abstract Supplement): 1118.1111.
125. Suzuki K, Nishioka J, Hayashi T, Kosaka Y (1988) Functionally active
thrombomodulin is present in human platelets. J Biochem 104: 628–632.
126. Slungaard A (2004) Platelet factor 4 modulation of the thrombomodulin-
protein C system. Crit Care Med 32: S331–335.
127. Cummins D, Fisher-Hoch SP, Walshe KJ, Mackie IJ, McCormick JB, et al.
(1989) A plasma inhibitor of platelet aggregation in patients with Lassa fever.
Br J Haematol 72: 543–548.
128. Cummins D, Molinas FC, Lerer G, Maiztegui JI, Faint R, et al. (1990) A
plasma inhibitor of platelet aggregation in patients with Argentine hemorrhagic
fever. Am J Trop Med Hyg 42: 470–475.
129. Marta RF, Heller MV, Maiztegui JI, Molinas FC (1993) Further studies on the
plasma inhibitor of platelet activation in Argentine hemorrhagic fever. Thromb
Haemost 69: 526–527.
130. Blair P, Flaumenhaft R (2009) Platelet alpha-granules: basic biology and
clinical correlates. Blood Rev 23: 177–189.
131. WHO (2013) Dengue control. Available: http://www.who.int/denguecontrol/
en/. Accessed 13 May 2014.
132. Mourya DT, Yadav PD, Sandhya VK, Reddy S (2013) Spread of Kyasanur
Forest disease, Bandipur Tiger Reserve, India, 2012–2013. Emerg Infect Dis
19: 1540–1541.
133. WHO (2010) Crimean-Congo haemorrhagic fever (CCHF) and Dengue in
Pakistan. Available: http://www.who.int/csr/don/2010_10_25a/en/. Ac-
cessed 13 May 2014.
134. WHO (2012) Rift Valley fever in Mauritania. Available: http://www.who.int/
csr/don/2012_11_01/en/. Accessed 13 May 2014.
135. CDC (2012) Outbreak postings. Available: http://www.cdc.gov/ncezid/
dhcpp/vspb/outbreaks.html. Accessed 13 May 2014.
136. Chen JP, Cosgriff TM (2000) Hemorrhagic fever virus-induced changes in
hemostasis and vascular biology. Blood Coagul Fibrinolysis 11: 461–483.
137. Fisher-Hoch S, McCormick JB, Sasso D, Craven RB (1988) Hematologic
dysfunction in Lassa fever. J Med Virol 26: 127–135.
138. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, et al. (1999) Markedly
elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10,
and tumor necrosis factor-alpha associated with fatal Ebola virus infection.
J Infect Dis 179 Suppl 1: S188–191.
139. Feldmann H, Klenk HD (1996) Filoviruses. In: Baron S, editor. Medical
Microbiology. 4th edition. Galveston (TX): University of Texas Medical
Branch at Galveston.
PLOS Neglected Tropical Diseases | www.plosntds.org 12 June 2014 | Volume 8 | Issue 6 | e2858
